Therini Bio
  • About
    • Leadership
    • Board of Directors
    • Advisory Board
    • Investors
  • Science
    • Overview
    • Pipeline
    • Publications
  • News
Select Page

Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases

Apr 29, 2025

Novel approach to treat neurodegenerative diseases by targeting fibrin-driven neuroinflammation was well-tolerated among healthy volunteers, with a clean hematological profile Half-life supports once-monthly dosing Data to be presented at AAIC 25 Sacramento, April 29,...

Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases

May 8, 2024

THN391 demonstrated effectiveness in protecting against vascular and neuronal degeneration – Therini Bio plans to initiate a Phase 1/2a trial evaluating THN391 in DME in 2H24 – The data was presented at ARVO 2024 –   Sacramento, May 8, 2024...

Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia

Oct 24, 2023

– THN391 was found to be safe and well-tolerated – – THN391 demonstrated a prolonged half-life and dose proportional Cmax levels – – The data will be presented October 25-27th at CTAD 2023 –   Sacramento, October 24, 2023...

Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease

May 15, 2023

– Industry Veteran Frank D. Lee Appointed as Executive Chairperson of the Board   SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory...

Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases

Apr 27, 2023

– Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials.   SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Therini Bio, Inc., a biotech company aimed at developing...

Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic

May 10, 2021

SOUTH SAN FRANCISCO, Calif, May 10, 2021 /PRNewswire/ — Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing. The capital will accelerate the development of Therini’s lead program – a monoclonal antibody against...
« Older Entries

Connect with Us

info@therinibio.com

2108 N ST, STE.# 4963

Sacramento, CA 95816


© 2024 – Therini Bio®, Inc.  |  Privacy Policy  |  Terms of Use  |  Financial Conflict of Interest Policy

Connect with Us

info@therinibio.com

2108 N ST, STE.# 4963

Sacramento, CA 95816
LinkedIn

© 2024 – Therini Bio®, Inc.
Privacy Policy  |  Terms of Use
Financial Conflict of Interest Policy

Add new entry logo

This website uses cookies to improve your experience. We\'ll assume you\'re ok with this, but you can opt-out if you wish. Read More

Accept Decline Cookie Settings
Cookies are small text files that can be used by websites to make a user\'s experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
    Name Domain Purpose Expiry Type
    wpl_user_preference www.therinibio.com WP GDPR Cookie Consent Preferences 1 year HTTP

  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.

  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.

  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.

Cookie Settings